UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 928, 2017

PhaseRx, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37772		20-4690620
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

410 W. Harrison Street, Suite 300 Seattle, Washington		98119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (206) 805-6300

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On November 928, 2017, PhaseRx, Inc. (the “Company”) issued a press release announcing ~~its~~that ~~financial~~the ~~results~~European Medicines Agency’s Committee for ~~the~~Orphan ~~third~~Medicinal Products ~~fiscal~~issued ~~quarter~~a ~~ended~~positive ~~September~~opinion ~~30,~~recommending orphan medicinal product (orphan drug) designation for PRX-ASL for the treatment ~~2017~~of argininosuccinate lyase deficiency. A copy of this press release is ~~furnished~~attached hereto as Exhibit 99.1 ~~hereto~~ and is incorporated herein by reference.

~~In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this~~ Item 29.~~02 of this Current Report on Form 8-K, including Exhibit 99~~01.1, ~~shall not~~Financial beStatements ~~deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section,~~ and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filingExhibits.

~~Item~~(d) ~~9.01 Financial Statements and~~ Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated November 28, 2017

Exhibit Number		Description
99.1		Press release dated November 9, 2017*

* This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PhaseRx, Inc.
Date: November 9, 2017	By:	/s/ Robert W. Overell
Date: November 28, 2017	By:	/s/ Robert W. Overell
		Robert W. Overell, Ph.D.
		Chief Executive Officer

Filing Compare · PHASERX, INC.